Share this article
Share this article
ResearchAndMarkets.com s offering.
The global ibuprofen market is projected to reach US$7.54 billion in 2024, progressing at a CAGR of 2.47%, over the period 2020-2024. The factors such as upsurge in healthcare expenditure, rising prevalence of arthritis, surging incidence of cancer cases, expanding urbanization and escalating sales of analgesic drugs would drive the growth of the market. However, the market growth would be challenged by adverse side effects and increase in the price of raw materials. A few notable trends include mounting e-commerce penetration, upswing in sports injuries, surging occurrence of chronic disorders and increasing public awareness.
Search jobs 11-Jan-2021 Anti-Rickettsial Treatment Market Outlook and Deep Study of Top Key Players | Allergan, Amneal Pharmaceuticals LLC., Strides Pharma Science Limited., Almirall, S.A
DBMR has added a new report titled Anti-Rickettsial Treatment Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The report forecasts the innovative applications of Anti-Rickettsial Treatment Market on the basis of these estimations. This market research analysis report starts with a basic introduction of the 2019 market segmentation, future scenario, industry growth rate, and industrial opportunities to 2028. Company profile comprises parameters such as company synopsis, commercial synopsis, work strategy and planning, SWOT analysis and present developments. The report gives out an outlook of the business chain structure and explains the industry environment, t
Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration. The drug major is recalling esomeprazole magnesium for delayed-release oral suspension in unit dose packets in strengths 10 mg, 20 mg and 40 mg in the US market, the latest Enforcement Report by the USFDA said. The drug firm has manufactured the affected lot at its Kurkumbh facility in Maharashtra and then supplied to its New Jersey-based subsidiary. The USFDA cited cross-contamination with other products as the reason for the company recalling the product.
Read more about Indices open on firm note; breadth strong on Business Standard. Local stocks are trading firm in early trade on buying demand in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was up 357.81 points or 0.74% at 48,451.13. The Nifty 50 index was up 112.35 points or 0.79% at 14,249.70.
Strides Pharma Science said that Aditya Puri has joined the Strides Group as an advisor and also as a director of its associate company, Stelis Biopharma.
Stelis Biopharma is a vertically integrated biopharmaceutical company. The company offers end-to-end state-of-the-art CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics.
A stalwart of the Indian banking and financial services industry, Aditya Puri was the founder-managing director and chief executive officer of HDFC Bank from its inception in 1994 until his retirement from the position in October 2020.
Prior to setting up HDFC Bank, he was chief executive officer of Citibank Malaysia with nearly two decades of overall banking experience across markets with Citibank.